Financing ·
Achieve Life Sciences reported a net loss of $74.8 million for Q2 2026, driven by a $48.7 million non-cash charge from…
ACHVAchieve Life Sciences, Inc.
Achieve Life Sciences reported a net loss of $74.8 million for Q2 2026, driven by a $48.7 million non-cash charge from warrant liability revaluation and increased G&A expenses to $14.6 million. The company closed a private placement raising up to $354 million, including $180 million upfront and warrants exercisable upon FDA approval of cytisinicline. Achieve received a Complete Response Letter for its NDA due to cGMP manufacturing observations at a prior facility; it has transitioned production to Adare Pharma Solutions in the U.S. and plans an NDA resubmission in Q4 2026, targeting potential FDA approval in H1 2027. The firm appointed Andrew D. Goldberg as CEO and added six new board members alongside senior commercial and quality leadership. Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing cytisinicline for nicotine dependence.